Abstract：Objective To investigate the occurrence risk of cardiac adverse events during Bortezomib treatment in patients with first-diagnosed multiple myeloma and risk factors analysis. Methods The medical records of 100 patients with multiple myeloma admitted to Dongtai People’s Hospital of Jiangsu Province from February 2020 to February 2022 were retrospectively analyzed. All patients were treated with Bortezomib as the basic induction chemotherapy drug, and were also treated with Ifosfamide. According to the monitoring results of cardiac adverse events during Bortezomib treatment, the patients were divided into cardiac adverse events occurrence group and non-occurrence group, and the risk factors affecting the occurrence of cardiac adverse events during Bortezomib treatment were analyzed. Results The incidence of central adverse events in 100 patients with first diagnosed multiple myeloma was 18.00%. There were no significant differences in gender, age, body mass index, pathological classification, Durie-Salmon stage, abnormal plasma cell proportion, bone lysis destruction, and blood calcium between two groups (P＞0.05); the levels of cardiac troponin I (cTnI), hypersensitive C-reactive protein (hs-CRP), and serum creatinine (Scr) in occurrence group were higher than those in non-occurrence group, and the level of hemoglobin (HGB) was lower than that in non-occurrence group (P＜0.05). The levels of cTnI (OR= 3.554), hs-CRP (OR=1.237), Scr (OR=1.067), and HGB (OR=0.930) were the influential factors for cardiac adverse events during Bortezomib treatment (P＜0.05). Conclusion The incidence of cardiac adverse events during Bortezomib treatment for the first multiple myeloma is relatively high, and the expression of cTnI, hs-CRP, Scr, and HGB are related to the occurrence of this event.
2023, Vol. 20 
京公网安备 11010502046598号